Baltimore, Maryland 21231

  • Endocrine System Diseases


The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.


Inclusion Criteria: - Have histologically or cytologically confirmed untreated metastatic pancreatic adenocarcinoma. - Patients with the presence of at least one measurable lesion. - Male or non-pregnant and non-lactating female of age >18 years. - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. - Patients must have adequate organ and marrow function defined by study-specified laboratory tests. - Must use acceptable form of birth control while on study. - Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: - Patients who will be considered for surgery are ineligible. - Patient who have had any prior chemotherapy within 5 years of enrollment. - Patient who have had radiotherapy for pancreatic cancer. - Age ≥ 76 years - Patient who is receiving or have received any other investigational agents within 28 days prior to Day 1 of treatment in this study. - Patient who has undergone major surgery, other than diagnostic surgery within 28 days prior to Day 1 of treatment in this study. - Patient who has known brain metastases. - Patient with history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel, capecitabine, cisplatin, or irinotecan. - Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Patient who has serious medical risk factors involving any of the major organ systems. - Patient who has known history of infection with HIV, hepatitis B, or hepatitis C. - Pregnant or breast feeding. - Patient is unwilling or unable to comply with study procedures - Patient with clinically significant wound.



Primary Contact:

Principal Investigator
Dung Le, MD
Johns Hopkins Medical Institution

Susan Sartorius-Mergenthaler, RN
Phone: 410-614-3644

Backup Contact:

Joann Santmyer, RN
Phone: (410) 583-2970

Location Contact:

Baltimore, Maryland 21231
United States

Susan Sartorius-Mergenthaler, RN
Phone: 410-614-3644

Site Status: Recruiting

Data Source:

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.